ChromaDex (CDXC) Receives FDA GRAS No Objection Letter for NIAGEN

August 15, 2016 6:32 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

ChromaDex Corp. (Nasdaq: CDXC) announced that the U.S. Food and Drug Administration (FDA) has issued a generally recognized as safe (GRAS) No Objection Letter, in response to the NIAGEN® nicotinamide riboside chloride (NR) GRAS filing, Notice No. GRN 000635.

Receipt of this No Objection Letter confirms that the FDA has no additional questions regarding this status. The GRAS status compliments the New Dietary Ingredient status already received for NIAGEN®.

NIAGEN® is already available in various supplements online and on select store shelves, but GRAS status defines it as a safe ingredient to use in food and beverage applications such as powdered beverages, protein shakes, nutrition bars, gum and chews. ChromaDex CEO and cofounder, Frank Jaksch Jr., commented, “We have been actively working with a number of manufacturers on early stage development projects to drive the commercialization of NIAGEN® into food and beverage products. The scientific research continues to validate the fact that NR is the most effective and efficient vitamin B3 at boosting NAD+, which increases cellular energy production and supports cellular health. This comes at a time when consumers are more interested than ever in finding products that will help them live longer and healthier throughout their lifetime.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Related Entities

Definitive Agreement

Add Your Comment